Incorporating molecular biomarkers into the continuum of care in chronic lymphocytic leukemia

Paul J. Hampel, Sameer A. Parikh, Timothy G. Call

Research output: Contribution to journalReview articlepeer-review

Abstract

Chronic lymphocytic leukemia (CLL) is a mature B-cell malignancy characterized by marked heterogeneity. Discoveries in disease biology over the past two decades have helped explain clinical variability and heralded the arrival of the targeted therapy era. In this article, we review improvements in risk stratification which have coincided with this progress, including individual biomarkers and their incorporation into prognostic models. Amidst an ever-expanding list of biomarkers, we seek to bring focus to the essential tests to improve patient care and counseling at particular times in the disease course, beginning with prognosis at diagnosis. The majority of patients do not require treatment at the time of diagnosis, making time-to-first-treatment a key initial prognostic concern. Prognostic and predictive biomarkers are then considered at subsequent major junctures, including at the time of treatment initiation, while on therapy, and at the time of relapse on novel agents.

Original languageEnglish (US)
JournalLeukemia and Lymphoma
DOIs
StateAccepted/In press - 2021

Keywords

  • Chronic lymphocytic leukemia
  • biomarker
  • prediction
  • prognosis
  • therapy

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Incorporating molecular biomarkers into the continuum of care in chronic lymphocytic leukemia'. Together they form a unique fingerprint.

Cite this